{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:32:03Z","timestamp":1791977523639,"version":"4.4.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0007173","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000}}],"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0007173","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T18:29:25Z","timestamp":1549909765000},"page":"e0007173","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":62,"title":["The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia \u2013 A review and meta-analysis"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-3590","authenticated-orcid":true,"given":"Joyce","family":"Pijpers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margriet L.","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk R.","family":"Essink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert","family":"Ritmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"e0005877","DOI":"10.1371\/journal.pntd.0005877","article-title":"Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme","volume":"11","author":"EE Zijlstra","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4269\/ajtmh.12-0711","article-title":"Clinical and Immunological Aspects of Post-Kala-Azar Dermal Leishmaniasis in Bangladesh","volume":"89","author":"S Islam","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"ref3","first-page":"6","article-title":"Post kala-azar dermal leishmaniasis: New observations challenge previous assumptions","volume":"5","year":"2007","journal-title":"ICDDR,B Heal Sci Bull"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cid\/cix245","article-title":"Inefectivity of Post-Kala-azar Dermal Leishmaniasis patients to sand flies: revisiting a Proof of Concept in the context of the Kala-azar Elimination Program in the Indian subcontinent","volume":"65","author":"R Molina","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"SUPPL. 1","key":"ref5","article-title":"Miltefosine\u2014discovery of the antileishmanial activity of phospholipid derivatives","volume":"100","author":"SL Croft","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"ref6","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"S Sundar","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/14728210903153862","article-title":"Developments in the treatment of visceral leishmaniasis","volume":"14","author":"ML den Boer","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"TPC Dorlo","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.trstmh.2006.02.011","article-title":"Oral miltefosine for the treatment of Indian visceral leishmaniasis","volume":"100","author":"S Sundar","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref10","unstructured":"National Vector Borne Disease Control Program. Guidelines for treatment of post-kala-azar dermal leishmaniasis. 2016."},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P). 2015 Statement","volume":"4","author":"D. Moher","year":"2015","journal-title":"Syst Rev"},{"key":"ref12","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4. U.S. Department of Health and Human Services;"},{"key":"ref13","unstructured":"IBM Corp. No TIBM SPSS Statistics for Macintosh. Version 25. New York; 2017."},{"key":"ref14","article-title":"Monitoring of parasite kinetics in Indian Post Kala Azar Dermal Leishmaniasis","author":"S Moulik","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0004093","article-title":"Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.","volume":"9","author":"V Ramesh","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/414378","article-title":"Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis","volume":"2015","author":"S Sundar","journal-title":"Sci World J"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4269\/ajtmh.14-0721","article-title":"Inadequacy of 12-week miltefosine treatment for Indian post-kala-azar dermal leishmaniasis","volume":"93","author":"S Ghosh","year":"2015","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/tmi.12015","article-title":"Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial","volume":"18","author":"S Sundar","year":"2013","journal-title":"Trop Med Int Heal"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2133.2011.10402.x","article-title":"Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis","volume":"165","author":"V Ramesh","journal-title":"Br J Dermatol"},{"issue":"3","key":"ref20","first-page":"199","article-title":"Miltefosine in post-kala azar dermal leishmaniasis (PKDL)","volume":"11","author":"D Modak","year":"2010","journal-title":"Journal, Indian Acad Clin Med"},{"issue":"24","key":"ref21","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis","volume":"341","author":"TK Jha","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis","volume":"196","author":"SK Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"ref23","first-page":"0","article-title":"Center for Drug Evaluation and Research","year":"2014","journal-title":"Approv Lett Nintedanib"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4103\/0022-3859.123161","article-title":"Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment","volume":"59","author":"K Pandey","journal-title":"J Postgrad Med"},{"issue":"80","key":"ref25","article-title":"Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh\u2019s National Kala-azar Elimination Programme","volume":"7","author":"S Hossain","year":"2018","journal-title":"Infect Dis Poverty"},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006781","article-title":"Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment","volume":"12","author":"S Maruf","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0959-8049(93)90177-H","article-title":"Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult\u2014an EORTC Soft Tissue and Bone Sarcoma Group Study","volume":"29A","author":"J Verweij","year":"1993","journal-title":"Eur J Cancer"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000217014","article-title":"Phase I study of weekly oral miltefosine (hexacyl-phosphocholine) in cancer patients","volume":"14","author":"S. Danhauser-Riedl","year":"1991","journal-title":"Oncoloy Res Treat"},{"issue":"4","key":"ref29","first-page":"245","article-title":"Daily oral Miltefosine (Hexadecyl-phosphocholine) in patients with advanced non-small cell lung cancer. A phase II study","volume":"13","author":"W E. Berdel","year":"1992","journal-title":"Oncol Res Treat"},{"key":"ref30","first-page":"260","article-title":"Daily Oral Miltefosine (Hexadecylphosphocholine) in Patients with Advanced Breast Cancer: A Phase II Study","author":"C Unger","year":"1993"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0959-8049(05)80142-X","article-title":"Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer","volume":"29A","author":"AS Planting","year":"1993","journal-title":"Eur J Cancer"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/BF01211805","article-title":"A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours","volume":"118","author":"J Verweij","year":"1992","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref33","article-title":"Highlights of Prescribing Information: Impavido","author":"Paladin Theraputics","year":"2014"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1086\/648726","article-title":"Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan","volume":"50","author":"PP a M van Thiel","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"9","key":"ref35","first-page":"1398","article-title":"Miltefosine for visceral and cutaneous leishmaniasis: Drug characteristics and evidence-based treatment recommendations","volume":"60","author":"B Monge-Maillo","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1186\/s12889-015-2424-8","article-title":"Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study","volume":"15","author":"V Ramesh","year":"2015","journal-title":"BMC Public Health"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/infdis\/jiu039","article-title":"Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure","volume":"210","author":"TPC Dorlo","year":"2014","journal-title":"J Infect Dis"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance","volume":"56","author":"S Rijal","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ref39","first-page":"e1657","article-title":"Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. Ghedin E, editor. PLoS Negl Trop Dis","volume":"6","author":"V Bhandari","year":"2012","journal-title":"Internet]"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0007173","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0007173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T13:37:19Z","timestamp":1589031439000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0007173"}},"subtitle":[],"editor":[{"given":"Shyam","family":"Sundar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0007173","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0007173","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,11]]}}}